{
    "nctId": "NCT03216447",
    "officialTitle": "A Prospective, Multi-center, Open-labeled, Randomized Clinical Trial of Patient Adherence and Convenience to Immunosuppressive Agents in Newly Liver Transplant Recipients to Compare QD Early Conversion and BID Tacrolimus Formulation.",
    "inclusionCriteria": "* Patient has been fully informed and has signed an IRB approved informed consent form within 7 days (Day 7-13) prior to POD 15 and is willing and able to follow study procedure\n* Patient is a primary liver transplant recipient\n* Patient is 20 to 70 years of age\n* Patient should be clearly conscious, fully understand and able to answer questionnaire\n* Must have minimum age of 18 Years\n* Must have maximum age of 70 Years",
    "exclusionCriteria": "* Patient has previously received or is receiving an organ transplant other than a liver.\n* Patient currently requires dialysis\n* Recipient or donor is known to be seropositive for human immunodeficiency virus (HIV)\n* Patient has received a liver transplant from a non-heart beating donor\n* Patient who is HCV negative has received an HCV positive (HCV RNA by PCR or HCV antibody) donor liver\n* Patient who is HbsAg negative has received an HbsAg positive (HBV DNA by PCR or HBV antibody) donor liver\n* Patient has received a liver transplant from a decrease donor \\> 70 years of age\n* Patient has a current malignancy or a history of malignancy (within the past 5 years), except hepatocellular carcinoma within UCSF Criteria and basal or non-metastatic squamous cell carcinoma of skin that has been treated successfully.\n* Patient is hemodynamically unstable on POD 15"
}